News

SAIC Reports Strong Earnings for Second Quarter FY 2025

SAIC Reports Strong Earnings for Second Quarter FY 2025

SAIC's Q2 FY 2025 Performance Overview

Science Applications International Corporation (SAIC) has released its financial results for the second quarter of fiscal year 2025, reporting revenues of $1.82 billion. This figure reflects an impressive 2% organic growth. The company also reported a net income of $81 million, along with an adjusted EBITDA of $170 million, which represents 9.4% of total revenues. Additionally, SAIC's diluted earnings per share were recorded at $1.58, while the adjusted diluted earnings per share stood at $2.05.

Insights from the CEO

SAIC's CEO, Toni Townes-Whitley, shared her thoughts on the company's performance, expressing her satisfaction with the results from the second quarter. She emphasized the strong achievements in various programs and the impressive cash generation. Townes-Whitley stated, "Our efforts to execute our growth strategy are showing encouraging trends, with our expanded pipeline of opportunities converting to more significant submissions and improving our book-to-bill metrics. We expect this positive momentum to continue into Fiscal Year 2026, supporting our ambitious targets for 2027."

Key Financial Highlights

Here are the key financial highlights for the second quarter:

  • Revenues rose by $34 million, or 2%, compared to the same quarter last year.
  • Operating income for the quarter was $134 million, equating to 7.4% of revenue.
  • Adjusted operating income experienced a slight decline to $164 million, or 9.0% of revenue.
  • Cash flows from operations were reported at $138 million, driven by effective working capital management.
  • During this period, the company generated free cash flow of $241 million.

Dividends and Shareholder Returns

After the conclusion of the quarter, SAIC's Board of Directors declared a cash dividend of $0.37 per share. This dividend is set to be paid on October 25, 2024, to shareholders on record as of October 11, 2024. This action underscores SAIC's commitment to providing value to its shareholders through consistent dividend payments and share buybacks.

Contract Wins and Backlog Update

SAIC reported net bookings of approximately $1.2 billion, resulting in a book-to-bill ratio of 0.6, with a trailing twelve months book-to-bill ratio of 1.1. By the end of the quarter, SAIC's estimated backlog reached about $22.9 billion, with around $4.2 billion classified as funded.

Recent Contract Wins

This quarter, SAIC secured notable contracts, including a $134 million task order from the U.S. Treasury for cloud services. The company also received significant recompete awards, such as a $206 million contract from the Department of Veterans Affairs and multiple contracts totaling $58 million from the U.S. Navy.

Fiscal Year 2025 Outlook

SAIC has raised its Adjusted Diluted EPS guidance for fiscal year 2025 to a range of $8.10 to $8.30, reflecting confidence in its strategic direction and operational execution. The company continues to reaffirm its overall financial guidance for fiscal year 2025, aiming for revenues between $7.35 billion and $7.50 billion, with an adjusted EBITDA margin of approximately 9.2% to 9.4%.

Frequently Asked Questions

1. What were the total revenues reported by SAIC for Q2 FY 2025?

SAIC reported total revenues of $1.82 billion for the second quarter of fiscal year 2025, reflecting a 2% increase year-over-year.

2. How did SAIC's earnings per share change in Q2 FY 2025?

SAIC's diluted earnings per share for the quarter were reported at $1.58, compared to $4.56 in the prior year's quarter.

3. What new contracts did SAIC secure during this quarter?

SAIC secured a $134 million task order from the U.S. Treasury and other contracts with the Department of Veterans Affairs and the U.S. Navy, totaling approximately $58 million.

4. What is SAIC's adjusted EPS guidance for FY 2025?

The adjusted diluted EPS guidance for fiscal year 2025 has been revised to a range of $8.10 to $8.30.

5. How much cash flow did SAIC generate in Q2 FY 2025?

SAIC generated free cash flow of $241 million during the second quarter of fiscal year 2025.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 181

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 81

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 275

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 343

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 337

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 291

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 310

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Beko Pushes for Policy Synergy Amidst Carbon Shakeup

Updated Category News Views 232

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 177

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 209

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading

Top 5 Most Recently Viewed Articles

McKinney's New Consumer PR Practice Sparks Marketing Buzz

Updated Category News Views 217

Market Dynamics Shifting: McKinney's Bold Move Let’s cut to the chase: McKinney’s launching a consumer PR practice—big deal, right? Well, hold your horses. This ain't just another agency spitting out press releases. They’re bringing in Jae Siercks, a heavy hitter from Weber Shandwick, to lead the charge. This kind of strategy echoes back to the days of the dot-com...

Continue Reading
Pariveda's Commitment: Winning Social Impact Partner Award

Updated Category News Views 218

Pariveda Recognized as Social Impact Partner of the Year Pariveda is proud to announce its recognition as the winner of the 2025 Geography and Global AWS Partner Award, highlighting its significant role as an innovator in the technology space. This prestigious award showcases the dedication of AWS Partners worldwide in advancing solutions using Amazon Web Services (AWS)....

Continue Reading
Eric A. Seiff: Celebrated Advocate in Criminal Defense for 2024

Updated Category News Views 179

Back in 2024, Eric A. Seiff was recognized among America’s Top 100 Criminal Defense Attorneys—a title only given to the absolute cream of the crop, with fewer than 0.5% of practicing attorneys making the cut. You gotta appreciate that level of distinction; it ain't just about being good—it’s about years spent fighting tooth and nail for what’s right in a...

Continue Reading
Wells Fargo Raises Price Target for Morgan Stanley Stock

Updated Category News Views 147

Wells Fargo Adjusts Morgan Stanley's Stock Outlook Recently, Wells Fargo reviewed its stance on Morgan Stanley (NYSE: MS), increasing the price target from $95.00 to $107.00. While this adjustment is a positive sign, the firm decided to keep an Underweight rating on the stock. The increase in the price target comes after Morgan Stanley's performance in the third quarter,...

Continue Reading
Raytone Biotech Begins RTP-008 Clinical Trial for Dry Eye Relief

Updated Category News Views 218

Raytone Biotech Begins RTP-008 Clinical Trial for Dry Eye Relief Raytone Biotech, a clinical-stage biotechnology company focused on innovative ophthalmic therapies, recently achieved a significant milestone by successfully completing the first patient dosing in its clinical trial for RTP-008. This new therapy is purposefully designed for those suffering from dry eye...

Continue Reading